Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
IOVA anticipates remarkable revenue growth in 2026 but hasn't actually provided guidance for 2026 at the current time. Potential competition from REPL's RP1 in melanoma looms, but IOVA's pipeline progress in new indications could offset concerns about competition in melanoma. Pressmaster/iStock via Getty Images Iovance Biotherapeutics ( IOVA ) has made progress on turning around the launch of Amtagvi (lifileucel) the past few quarters and is speaking about 2026 performance in an upbeat fashion. I rated IOVA a hold IOVA posted record Amtagvi revenue (~$65M, 13% QoQ growth) and improved gross margin to 50%, with management expressing confidence in accelerating demand and operational gains for 2026. A potential FDA approval for REPL's RP1 in melanoma could pressure IOVA, but rapid progress in NSCLC and sarcoma indications—both with fast-track or registrational trials—provide significant 2027 catalysts. Despite a high 2025 cash burn, IOVA guides cash runway into Q3'27, aided
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics (IOVA) was upgraded by Truist Financial Corporation to "hold".MarketBeat
- Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas [Yahoo! Finance]Yahoo! Finance
- Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/24/26 - Beat
IOVA
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 3/11/26 - Form 4
- IOVA's page on the SEC website